Abstract
We investigated the in vitro and in vivo antimicrobial potential of a selective serotonin reuptake inhibitor sertraline hydrochloride, against clinical isolates of bacteria and Candida species. Minimum Inhibitory Concentration of sertraline against 161 human isolates of 12 Gram negative and 5 Gram positive genera, Candida albicans ATCC10231 and Candida tropicalis ATCC13803 was determined by spot inoculation, broth and agar dilution methods along with its postantibiotic effect following a short drug exposure. The toxicity and protective efficacy was tested in vivo with a mousevirulent strain of Salmonella typhimurium NCTC74.The MIC was 20-200μg/ml for bacteria, and 200μg/ml for Candida. The growth inhibitory study with Bacillus subtilis UC564 and Shigella dysenteriae NCTC599/52 revealed that the drug is bacteriostatic at its MIC and cidal at higher concentrations. Study on its post-antibiotic effect following a short drug exposure revealed that Sertraline has a time- and dose-dependent effect. Treatment for 4h at concentrations below and equipotent to the minimal static concentration resulted in a lag of regrowth at 8-24h for Candida isolates. The in vivo study with Salmonella typhimurium in Swiss mice showed that the median lethal dose was 1.9 x 107 cfu and 50 LD50 was 0.95x109. Interestingly, the drug at a non-toxic single dose provides significant protection (P<0.001) to the mice challenged with S. typhimurium. Sertraline remarkably reduced the number of viable bacteria in organ homogenates and blood of the treated animals and demonstrate both in vitro and in vivo antibacterial potential at lower dose than its predesignated pharmacological activity.
Keywords: Sertraline hydrochloride, SSRI, antibacterial activity, antifungal activity, non-antibiotic
Anti-Infective Agents
Title:Evaluation of In Vivo and In Vitro Antimicrobial Activities of a Selective Serotonin Reuptake Inhibitor Sertraline Hydrochloride
Volume: 10 Issue: 2
Author(s): Amalesh Samanta, Debprasad Chattopadhyay, Chandrima Sinha, Ananda Dulal Jana, Soma Ghosh, Anurup Mandal, Ananya Banerjee, Oliver Hendricks, Jorn B. Christensen and Jette Elisabeth Kristiansen
Affiliation:
Keywords: Sertraline hydrochloride, SSRI, antibacterial activity, antifungal activity, non-antibiotic
Abstract: We investigated the in vitro and in vivo antimicrobial potential of a selective serotonin reuptake inhibitor sertraline hydrochloride, against clinical isolates of bacteria and Candida species. Minimum Inhibitory Concentration of sertraline against 161 human isolates of 12 Gram negative and 5 Gram positive genera, Candida albicans ATCC10231 and Candida tropicalis ATCC13803 was determined by spot inoculation, broth and agar dilution methods along with its postantibiotic effect following a short drug exposure. The toxicity and protective efficacy was tested in vivo with a mousevirulent strain of Salmonella typhimurium NCTC74.The MIC was 20-200μg/ml for bacteria, and 200μg/ml for Candida. The growth inhibitory study with Bacillus subtilis UC564 and Shigella dysenteriae NCTC599/52 revealed that the drug is bacteriostatic at its MIC and cidal at higher concentrations. Study on its post-antibiotic effect following a short drug exposure revealed that Sertraline has a time- and dose-dependent effect. Treatment for 4h at concentrations below and equipotent to the minimal static concentration resulted in a lag of regrowth at 8-24h for Candida isolates. The in vivo study with Salmonella typhimurium in Swiss mice showed that the median lethal dose was 1.9 x 107 cfu and 50 LD50 was 0.95x109. Interestingly, the drug at a non-toxic single dose provides significant protection (P<0.001) to the mice challenged with S. typhimurium. Sertraline remarkably reduced the number of viable bacteria in organ homogenates and blood of the treated animals and demonstrate both in vitro and in vivo antibacterial potential at lower dose than its predesignated pharmacological activity.
Export Options
About this article
Cite this article as:
Samanta Amalesh, Chattopadhyay Debprasad, Sinha Chandrima, Dulal Jana Ananda, Ghosh Soma, Mandal Anurup, Banerjee Ananya, Hendricks Oliver, B. Christensen Jorn and Elisabeth Kristiansen Jette, Evaluation of In Vivo and In Vitro Antimicrobial Activities of a Selective Serotonin Reuptake Inhibitor Sertraline Hydrochloride, Anti-Infective Agents 2012; 10 (2) . https://dx.doi.org/10.2174/2211362611208020095
DOI https://dx.doi.org/10.2174/2211362611208020095 |
Print ISSN 2211-3525 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-3533 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Characterization of the Effect of a Novel γ-secretase Modulator on Aβ: A Clinically Translatable Model
Current Pharmaceutical Design Motor and Non-Motor Features of Parkinson’s Disease – A Review of Clinical and Experimental Studies
CNS & Neurological Disorders - Drug Targets Advent of Proteomic Tools for Diagnostic Biomarker Analysis in Alzheimer’s Disease
Current Protein & Peptide Science Lafora Progressive Myoclonus Epilepsy: Recent Insights into Cell Degeneration
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Conference Report: Summary Report of the International Association of Neurorestoratology VII Conference: Regulations, Ethics, Science, and the Need of Patients Care in Neurorestoratology
CNS & Neurological Disorders - Drug Targets Anti-inflammatory Effects of Dietary Antioxidants
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Protective Effect of Vitamin B Therapy on Bone and Cardiovascular Disease
Recent Patents on Cardiovascular Drug Discovery Neuroprotective effects of the securinine-analogues: identification of Allomargaritarine as a lead compound
CNS & Neurological Disorders - Drug Targets Whole body vibration training improves walking performance of stroke patients with knee hyperextension: a randomized controlled pilot study
CNS & Neurological Disorders - Drug Targets Docking-based 3D-QSAR Studies of Phosphodiesterase 9A Inhibitors
Letters in Drug Design & Discovery Current Concepts on Selected Plant Secondary Metabolites With Promising Inhibitory Effects Against Enzymes Linked to Alzheimer’s Disease
Current Medicinal Chemistry Does Parkinson’s Disease and Type-2 Diabetes Mellitus Present Common Pathophysiological Mechanisms and Treatments?
CNS & Neurological Disorders - Drug Targets Docosahexaenoic Acid-Phosphatidylcholine Improves Cognitive Deficits in an Aβ<sub>23-35</sub>-Induced Alzheimer’s Disease Rat Model
Current Topics in Medicinal Chemistry Meet Our Editorial Board Member
Current Hypertension Reviews Von Willebrand Factor and Thrombosis: Risk Factor, Actor and Pharmacological Target
Current Vascular Pharmacology The NMDA Receptor NR2B Subunit: A Valid Therapeutic Target for Multiple CNS Pathologies
Current Medicinal Chemistry Cytokines in Neuroinflammation and Alzheimers Disease
Current Drug Targets Vitamin D and Stroke: Promise for Prevention and Better Outcome
Current Vascular Pharmacology Cellular Mechanisms of Brain Injury and Cell Death
Current Pharmaceutical Design Nicotinic Receptors in Neurodegeneration
Current Neuropharmacology